Lexeo Therapeutics presents LX2006 data showing sustained cardiac improvements in Friedreich ataxia
LXEO•Lexeo Therapeutics reported a 25% reduction in mean left ventricular mass index at 24 months among six LX2006 participants with abnormal baseline readings. The company expects pivotal trial topline data in the second half of 2027 and is targeting a potential accelerated-approval application for the first half of 2028.
1. LX2006 results and plans
Across 17 participants, LX2006 had no Grade 3 treatment-related serious adverse events; one possibly treatment-related Grade 2 asymptomatic myocarditis event occurred. Lexeo expects LX2006 pivotal trial topline data in the second half of 2027 and is targeting a potential accelerated-approval application for the first half of 2028. An LX2020 pivotal study is anticipated in the second half of 2027, with protocol finalization expected in the first half; cash runway extends into 2028.




